Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 1:00 p.m. on August 7, 2009 through August 14, 2009. To listen to the audio replay, dial 888-286-8010 (U.S. or Canada) or 617-801-6888 (international) and use access code 93256887.
A live webcast of the conference call will be available on the Company's website and will be archived for 30 days. To access the webcast or the replay, go to www.genvec.com, click on "Investor Relations," and click on "Webcasts and Data."
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.
Statements herein relating to future financial or business performance, conditions or strategies and other financial and business mattePage: 1 2 3 4 5 6 7 Related biology technology :1
. GenVec Expands Contract Supporting Malaria Vaccine Program2
. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants3
. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights4
. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights5
. OncoGenex Reports Second Quarter 2009 Financial Results6
. Repligen Reports First Quarter Fiscal Year 2010 Financial Results7
. PDI Reports 2009 Second Quarter Financial Results8
. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results9
. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results10
. NxStage Reports Second Quarter 2009 Financial Results11
. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia